Welcome to our dedicated page for Boston Scien Cp SEC filings (Ticker: BSX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Boston Scientific Corporation (NYSE: BSX) files a broad range of reports and disclosures with the U.S. Securities and Exchange Commission, providing detailed insight into its operations as a global medical technology company. These SEC filings cover topics such as financial performance, material acquisitions, executive compensation programs, governance changes and risk factors relevant to the business.
On this page, you can review Boston Scientific’s current reports on Form 8-K, which the company uses to announce material events. Recent 8-K filings describe the definitive agreement to acquire Penumbra, Inc., including references to a joint press release and investor presentation, as well as the adoption of a 2026 annual bonus plan and performance share programs tied to metrics like global sales, adjusted earnings per share, relative total shareholder return and organic net sales growth. Other 8-Ks report quarterly financial results, director retirement plans and changes in senior leadership roles.
In addition to 8-Ks, Boston Scientific’s annual reports on Form 10-K and quarterly reports on Form 10-Q (accessible via the SEC’s EDGAR system) include consolidated financial statements, segment and geographic net sales data, discussions of MedSurg and Cardiovascular businesses, and extensive risk factor sections. These filings also explain the company’s use of non-GAAP financial measures such as operational and organic net sales growth and adjusted earnings per share, with reconciliations to GAAP figures.
Stock Titan enhances these regulatory documents with AI-powered summaries that highlight key points from lengthy filings, helping readers quickly identify information on acquisitions, compensation plans, performance metrics and risk disclosures. Real-time updates from EDGAR ensure that new Boston Scientific filings, including Forms 10-K, 10-Q and 4 (insider transaction reports), are added as they become available, while AI-generated explanations assist in interpreting complex financial and legal language.
Boston Scientific EVP Arthur C. Butcher reported multiple equity transactions in company stock and units. On February 13, 2026, he acquired 25,380 shares of common stock in two grant or award acquisitions, and also acquired shares through exercises of restricted stock units tied to long‑term incentive programs. He disposed of 25,150 shares of common stock on February 13, 2026 and smaller amounts on later dates to cover tax liabilities at $74.73 per share. Following these moves, he directly held 55,792 shares of common stock and indirectly held 13,354 shares through the company 401(k) plan.
Boston Scientific EVP, GC and Corporate Secretary Vance R. Brown reported multiple equity compensation transactions. On February 13–16, 2026, he acquired Boston Scientific common stock through the exercise and conversion of restricted stock units and performance share units, and through grants and awards, all at a stated price of $0.00 per share.
On these dates, shares of common stock were also disposed of at $74.73 per share to satisfy tax liabilities by delivering securities. Footnotes explain that performance share units granted on February 14, 2023 vested based on three-year total shareholder return and organic net sales performance through December 31, 2025, subject to a three-year service period satisfied on February 13, 2026. Each restricted stock unit represents a commitment to issue one share in four equal annual installments beginning on specified anniversaries of the grant dates.
Boston Scientific SVP and Chief HR Officer Miriam O'Sullivan reported several equity compensation transactions dated February 12, 2026. She acquired 961 shares of Boston Scientific common stock at $0.0000 through the exercise of restricted stock units, then had 338 shares withheld at $74.12 per share to cover tax obligations, leaving 15,420 directly held shares plus 1,731 held indirectly by her spouse.
On the derivative side, she exercised 961 restricted stock units, ending with 1,924 restricted stock units directly owned. She also received a new grant of 4,722 restricted stock units and a stock option award for 11,143 shares. The restricted stock units and options vest in four equal annual installments beginning on February 12, 2027, with the earlier RSU grant delivering shares in four equal installments starting February 12, 2025.
Boston Scientific SVP Emily Woodworth reported multiple equity awards and an RSU exercise. On February 12, 2026, she exercised 481 restricted stock units into 481 common shares at an exercise price of $0.0000 and had 242 shares withheld at $74.12 per share to cover tax obligations, leaving 951 common shares directly owned. She also received 6,071 new restricted stock units and a grant of 5,584 stock options with a $74.12 exercise price, each vesting in four equal annual installments starting February 12, 2027.
Boston Scientific executive Padraig Andrew O'Connor, EVP Global Operations, reported several equity compensation transactions dated February 12, 2026. He exercised 1,058 restricted stock units into common shares and had 457 shares withheld at $74.12 per share to cover tax obligations, leaving 4,486 common shares directly owned.
He now directly holds 2,116 restricted stock units from earlier awards. On the same date, he received a new grant of 5,059 restricted stock units and 11,939 stock options. The RSUs and options vest in four equal annual installments beginning on February 12, 2027, with each unit or option tied to one share of common stock.
Boston Scientific EVP and CFO Jonathan Monson reported several equity transactions on February 12, 2026. He exercised 1,154 restricted stock units into common shares at a conversion price of $0.0000, then had 573 common shares withheld at $74.12 per share to cover tax obligations, leaving 35,870 common shares held directly.
Monson also acquired new equity awards. He received 11,805 restricted stock units, each representing one future share of Boston Scientific common stock, and was granted stock options for 27,857 shares. Both the new RSUs and options vest in four equal annual installments beginning February 12, 2027.
Boston Scientific Chairman, President & CEO Michael F. Mahoney reported several equity compensation transactions dated February 12, 2026. He acquired 13,704 shares of common stock through the exercise of restricted stock units at $0.0000 per share, then disposed of 6,626 shares at $74.12 per share to cover tax obligations, leaving 1,418,813 common shares held directly.
Mahoney also received a new grant of 55,652 restricted stock units and a stock option for 131,329 shares with an exercise price of $74.12 per share, both vesting in four equal annual installments beginning February 12, 2027. In addition, 213,679 common shares are held indirectly in a trust.
Boston Scientific EVP & Group President, Cardiology Joseph Michael Fitzgerald reported equity compensation and related share movements. On February 12, 2026, he exercised 3,462 restricted stock units, receiving the same number of Boston Scientific common shares. To cover tax obligations, 1,612 common shares were disposed of at $74.12 per share through share withholding, leaving him with 169,892 common shares held directly. He also received new awards of 18,550 restricted stock units and a stock option for 43,776 shares, each vesting in four equal annual installments beginning on February 12, 2027. Following these transactions, he directly holds 6,924 restricted stock units and 18,550 restricted stock units from the new grant, plus the 43,776-share stock option. An additional 5,234 common shares are reported as held indirectly by his child, and he disclaims beneficial ownership of those shares.
Butcher Arthur C reported multiple insider transaction types in a Form 4 filing for BSX. The filing lists transactions totaling 57,681 shares at a weighted average price of $74.12 per share. Following the reported transactions, holdings were 5,386 shares.
Boston Scientific executive Vance R. Brown, EVP, GC and Corporate Secretary, reported equity compensation changes tied to restricted stock units and options. On February 12, 2026, 1,442 restricted stock units were exercised into 1,442 shares of common stock, and 488 shares were disposed of to cover tax withholding at $74.12 per share.
Following these transactions, Brown directly held 34,405 shares of common stock. He also received new grants of 7,420 restricted stock units and 17,510 stock options with a $74.12 exercise price, each vesting in four equal annual installments beginning February 12, 2027.